Related Experiment Video
Updated: Jul 12, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Vector-Transmitted Flaviviruses: An Antiviral Molecules Overview
Erica Diani1, Anna Lagni1, Virginia Lotti1
1Department of Diagnostic and Public Health, Microbiology Section, University of Verona, 37134 Verona, Italy.
Abstract:
Flaviviruses cause numerous pathologies in humans across a broad clinical spectrum with potentially severe clinical manifestations, including hemorrhagic and neurological disorders. Among human flaviviruses, some viral proteins show high conservation and are good candidates as targets for drug design. From an epidemiological point of view, flaviviruses cause more than 400 million cases of infection worldwide each year. In particular, the Yellow Fever, dengue, West Nile, and Zika viruses have high morbidity and mortality-about an estimated 20,000 deaths per year. As they depend on human vectors, they have expanded their geographical range in recent years due to altered climatic and social conditions. Despite these epidemiological and clinical premises, there are limited antiviral treatments for these infections. In this review, we describe the major compounds that are currently under evaluation for the treatment of flavivirus infections and the challenges faced during clinical trials, outlining their mechanisms of action in order to present an overview of ongoing studies. According to our review, the absence of approved antivirals for flaviviruses led to in vitro and in vivo experiments aimed at identifying compounds that can interfere with one or more viral cycle steps. Still, the currently unavailability of approved antivirals poses a significant public health issue.
Insights
Flaviviruses cause millions of infections yearly, with limited treatments available. This review explores promising antiviral compounds and challenges in developing effective flavivirus therapies.
Area of Science:
- Virology
- Infectious Diseases
- Drug Discovery
Background:
- Flaviviruses cause significant global health issues, including Yellow Fever, dengue, West Nile, and Zika, leading to severe pathologies and an estimated 20,000 deaths annually.
- Expanding geographical ranges due to climate and social factors increase flavivirus transmission.
- Limited approved antiviral treatments exist for flavivirus infections, highlighting an urgent public health need.
Purpose of the Study:
- To review current compounds under evaluation for treating flavivirus infections.
- To outline the mechanisms of action for potential antiviral agents.
- To discuss challenges encountered in clinical trials for flavivirus drug development.
Main Methods:
- Literature review of ongoing studies and clinical trials for flavivirus antivirals.
- Analysis of identified compounds targeting various steps of the viral life cycle.
- Examination of challenges in flavivirus drug development and clinical evaluation.
Main Results:
- Numerous compounds are being investigated in vitro and in vivo to inhibit flavivirus replication.
- Several viral proteins exhibit high conservation, presenting viable targets for drug design.
- The absence of approved antivirals remains a critical public health concern.
Conclusions:
- Despite ongoing research, there is a significant lack of approved antiviral therapies for flaviviruses.
- Identifying and developing effective treatments for flavivirus infections is crucial due to their widespread impact.
- Further research and clinical trials are necessary to overcome challenges and bring new antivirals to patients.
Related Concept Videos
Viruses with RNA Genomes
Viral Structure
Subviral Agents
Retroviruses
Retrovirus Life Cycles
Introduction to Virus

